User fee raise of about 20% under discussion between FDA and industry.
FDA/INDUSTRY USER FEE REAUTHORIZATION DISCUSSIONS FOCUSING ON 20% RAISE in user fees as the agency and brand name pharmaceutical industry seek to reach an agreement in time for the opening of the 105th Congress. FDA is understood to have been seeking roughly a doubling of the fees in exchange for expanded services. The agency, however, could be willing to accept an increase of about 20% to cover a lesser package of commitments on the review process.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth